7 completed. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 3 | Completed 3 |
Follow mapatumumab: new trials by email Literature Review of mapatumumab trials Research Report on mapatumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Mapatumumab, Placebo, Sorafenib - Carcinoma, Hepatocellular | Phase 1 / Phase 2 | Completed | Human Genome Sciences Inc., a GSK Company | 101 | 2011-02-08 | 2018-12-19 |
| Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer mapatumumab, cisplatin, radiotherapy - Advanced Cervical Cancer | Phase 1 / Phase 2 | Completed | University Medical Center Groningen | 9 | 2010-03-01 | 2024-04-19 |
| A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma mapatumumab, sorafenib - Hepatocellular Carcinoma | Phase 1 | Completed | Human Genome Sciences Inc., a GSK Company | 23 | 2008-06-01 | 2012-10-30 |
| A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer Mapatumumab, Paclitaxel, Carboplatin - Non Small Cell Lung Cancer | Phase 2 | Completed | Human Genome Sciences Inc. | 111 | 2007-01-01 | 2013-08-08 |
| Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma Mapatumumab, Bortezomib - Multiple Myeloma | Phase 2 | Completed | Human Genome Sciences Inc. | 105 | 2006-05-01 | 2013-08-08 |
| Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) TRAIL-R1 mAb (TRM-1; HGS-ETR1) - Lymphoma, Non-Hodgkin | Phase 2 | Completed | Human Genome Sciences Inc. | 2004-06-01 | 2013-08-02 | |
| Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) TRAIL-R1 mAb (TRM-1;HGS-ETR1) - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Human Genome Sciences Inc. | 2013-08-02 |
Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Liver Neoplasms (1) · Lung Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Uterine Cervical Neoplasms (1)
Human Genome Sciences Inc. (4) · Human Genome Sciences Inc., a GSK Company (2) · University Medical Center Groningen (1)
United States (6) · Germany (2) · Romania (2) · Australia (1) · Canada (1) · Hungary (1) · India (1) · Netherlands (1) · Poland (1) · Puerto Rico (1) · Russia (1) · Ukraine (1)
An KL Reyners, MD,PhD (1) · Norma Lynn Fox, PhD (1)
2009 (1)